Transcode Therapeutics Stock Working Capital
| RNAZ Stock | USD 0.67 0.06 9.84% |
Transcode Therapeutics fundamentals help investors to digest information that contributes to Transcode Therapeutics' financial success or failures. It also enables traders to predict the movement of Transcode Stock. The fundamental analysis module provides a way to measure Transcode Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transcode Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 964.8 K | 916.6 K | |
| Change In Working Capital | -1.1 M | -1 M |
Transcode | Working Capital |
Transcode Therapeutics Company Working Capital Analysis
Transcode Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Transcode Therapeutics Working Capital | 964.85 K |
Most of Transcode Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transcode Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Transcode Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as Working Capital. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Transcode Net Invested Capital
Net Invested Capital |
|
Based on the company's disclosures, Transcode Therapeutics has a Working Capital of 964.85 K. This is 99.77% lower than that of the Biotechnology sector and 99.82% lower than that of the Health Care industry. The working capital for all United States stocks is 99.93% higher than that of the company.
Transcode Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transcode Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics of similar companies.Transcode Therapeutics is currently under evaluation in working capital category among its peers.
Transcode Fundamentals
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 | ||||
| Current Valuation | 7.49 M | ||||
| Shares Outstanding | 17.27 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 11.46 % | ||||
| Number Of Shares Shorted | 1.38 M | ||||
| Price To Book | 8.03 X | ||||
| EBITDA | (18.9 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 450.57 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (18.07 M) | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | 268.14 X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 10.53 M | ||||
| Total Asset | 5.17 M | ||||
| Retained Earnings | (46.42 M) | ||||
| Working Capital | 964.85 K | ||||
| Net Asset | 5.17 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| V | Visa Class A | |
| MSFT | Microsoft |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.